The world of autism treatment has been abuzz with controversy, as parents desperately seek a cure for their children's autism. The spotlight is on leucovorin, a derivative of vitamin B9, which has sparked a divide between parents and medical professionals.
In a recent press conference, federal health officials touted leucovorin as a potential treatment for autism, sending parents on a quest for this elusive cure. Swathi Balantrapu, a mother of an autistic child, is one such parent who has embarked on a journey of exploring various treatments, from ABA therapy to stem cell therapy in Germany.
The announcement by the Trump administration created a ripple effect, with parents clamoring for the drug and social media groups popping up to share information and referrals. However, major medical groups have advised against its routine prescription, putting doctors in a difficult position.
Dr. Shafali Jeste, an autism researcher, highlights the burden this places on clinicians, who now have to explain and interpret the onslaught of information. She believes the administration's messaging was misleading and that the enthusiasm around the drug will take a long time to subside.
The initial claim that leucovorin could treat autism was based on a small study, and experts argue that the evidence is insufficient. Yet, demand for the drug has skyrocketed, with prescriptions increasing by 71% in the last quarter of 2025.
Many doctors are struggling with the demand for a drug that was once outside the realm of autism care. Major medical associations and health systems have issued guidance against its use, citing a lack of evidence. However, some doctors at large health systems are prescribing it selectively, fearing backlash from colleagues.
One concern is the unintended consequences of prescribing leucovorin, which is commonly used in cancer treatment. Oncologists worry about potential shortages for cancer patients who rely on the drug.
While some parents have found private practitioners who will prescribe leucovorin, the cost of these appointments can be significant. Balantrapu, for example, was quoted a price of $1,896 for an initial visit, which she found shocking.
The debate over leucovorin highlights the delicate balance between maintaining parents' trust and sticking to evidence-based medicine. Doctors are faced with a challenging decision: to prescribe or not to prescribe.
Dr. Jeste argues that prescribing leucovorin could set a slippery precedent, opening the door to other poorly studied treatments. On the other hand, clinicians like Dr. Richard Frye, a vocal proponent of leucovorin, believe the drug is safe and has incredible potential.
The consequences of this decision are far-reaching, impacting not only the patient-doctor relationship but also the availability of resources for evidence-based interventions like ABA therapy. As the debate rages on, parents continue to navigate a complex landscape, seeking the best possible care for their children.
